ARTICLE SUMMARY:
The precision oncology market is estimated to be $80-100 billion, with less than 20% penetration. In a video interview, Kyle Mikson of Canaccord Genuity explains how top competitors like Guardant Health, Natera, Grail, Tempus, GeneDx, and others are set to benefit and the catalysts driving adoption.
The diagnostics industry has undergone enormous changes and continues to evolve from a technology and business perspective, with enormous implications for clinical care. A group of new players is driving innovation, particularly impacting precision oncology, but also making inroads into neurodegeneration, autoimmune and other chronic diseases. Molecular testing is mainstream and expanding, and artificial intelligence, along with spatial biology and single-cell analysis technologies are further transforming the field.
But the business models remain complicated with a lot of confounding factors due to FDA uncertainty, shifting regulatory agenda, reimbursement pressures, and shortcomings in test performance versus expectations.
Kyle Mikson, a managing director and senior research analyst for Canaccord Genuity, is one of the most insightful, experienced diagnostics industry analysts on Wall Street. In a video interview with MedTech Strategist, he discusses the diagnostics competitive landscape, trends driving adoption, and types of applications, and opportunities in a shifting market.
